Cargando…
Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vacci...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251722/ https://www.ncbi.nlm.nih.gov/pubmed/37346050 http://dx.doi.org/10.1016/j.isci.2023.107084 |
_version_ | 1785056003305242624 |
---|---|
author | Wolff, Anette S.B. Hansen, Lena Grytaas, Marianne Aa. Oftedal, Bergithe E. Breivik, Lars Zhou, Fan Hufthammer, Karl Ove Sjøgren, Thea Olofsson, Jan Stefan Trieu, Mai Chi Meager, Anthony Jørgensen, Anders P. Lima, Kari Greve-Isdahl Mohn, Kristin Langeland, Nina Cox, Rebecca Jane Husebye, Eystein S. |
author_facet | Wolff, Anette S.B. Hansen, Lena Grytaas, Marianne Aa. Oftedal, Bergithe E. Breivik, Lars Zhou, Fan Hufthammer, Karl Ove Sjøgren, Thea Olofsson, Jan Stefan Trieu, Mai Chi Meager, Anthony Jørgensen, Anders P. Lima, Kari Greve-Isdahl Mohn, Kristin Langeland, Nina Cox, Rebecca Jane Husebye, Eystein S. |
author_sort | Wolff, Anette S.B. |
collection | PubMed |
description | A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vaccine tolerability and immune responses in a large cohort of patients with APS-1 (N = 33) and how these vaccinated patients coped with subsequent infections. We report that adult patients with APS-1 were able to mount adequate SARS-CoV-2 spike-specific antibody responses after vaccination and observed no signs of decreased tolerability. Compared with age- and gender-matched healthy controls, patients with APS-1 had considerably lower peak antibody responses resembling elderly persons, but antibody decline was more rapid in the elderly. We demonstrate that vaccination protected patients with APS-1 from severe illness when infected with SARS-CoV-2 virus, overriding the systemic danger of IFN-I autoantibodies observed in previous studies. |
format | Online Article Text |
id | pubmed-10251722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-102517222023-06-09 Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies Wolff, Anette S.B. Hansen, Lena Grytaas, Marianne Aa. Oftedal, Bergithe E. Breivik, Lars Zhou, Fan Hufthammer, Karl Ove Sjøgren, Thea Olofsson, Jan Stefan Trieu, Mai Chi Meager, Anthony Jørgensen, Anders P. Lima, Kari Greve-Isdahl Mohn, Kristin Langeland, Nina Cox, Rebecca Jane Husebye, Eystein S. iScience Article A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vaccine tolerability and immune responses in a large cohort of patients with APS-1 (N = 33) and how these vaccinated patients coped with subsequent infections. We report that adult patients with APS-1 were able to mount adequate SARS-CoV-2 spike-specific antibody responses after vaccination and observed no signs of decreased tolerability. Compared with age- and gender-matched healthy controls, patients with APS-1 had considerably lower peak antibody responses resembling elderly persons, but antibody decline was more rapid in the elderly. We demonstrate that vaccination protected patients with APS-1 from severe illness when infected with SARS-CoV-2 virus, overriding the systemic danger of IFN-I autoantibodies observed in previous studies. Elsevier 2023-06-09 /pmc/articles/PMC10251722/ /pubmed/37346050 http://dx.doi.org/10.1016/j.isci.2023.107084 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wolff, Anette S.B. Hansen, Lena Grytaas, Marianne Aa. Oftedal, Bergithe E. Breivik, Lars Zhou, Fan Hufthammer, Karl Ove Sjøgren, Thea Olofsson, Jan Stefan Trieu, Mai Chi Meager, Anthony Jørgensen, Anders P. Lima, Kari Greve-Isdahl Mohn, Kristin Langeland, Nina Cox, Rebecca Jane Husebye, Eystein S. Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies |
title | Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies |
title_full | Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies |
title_fullStr | Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies |
title_full_unstemmed | Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies |
title_short | Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies |
title_sort | vaccination prevents severe covid-19 outcome in patients with neutralizing type 1 interferon autoantibodies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251722/ https://www.ncbi.nlm.nih.gov/pubmed/37346050 http://dx.doi.org/10.1016/j.isci.2023.107084 |
work_keys_str_mv | AT wolffanettesb vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT hansenlena vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT grytaasmarianneaa vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT oftedalbergithee vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT breiviklars vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT zhoufan vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT hufthammerkarlove vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT sjøgrenthea vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT olofssonjanstefan vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT trieumaichi vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT meageranthony vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT jørgensenandersp vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT limakari vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT greveisdahlmohnkristin vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT langelandnina vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT coxrebeccajane vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies AT husebyeeysteins vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies |